Vimarsana
Biggest News Aggregation in the World

Page 3 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Head to Head Contrast: Innate Pharma (NASDAQ:IPHA) vs. Editas Medicine (NASDAQ:EDIT) - Vimarsana News

Head to Head Contrast: Innate Pharma (NASDAQ:IPHA) vs. Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ:EDIT – Get Free Report) and Innate Pharma (NASDAQ:IPHA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Institutional & Insider Ownership 76.6% of Editas […]

Keystone Financial Group Purchases New Shares in Editas Medicine, Inc. (NASDAQ:EDIT) - Vimarsana News

Keystone Financial Group Purchases New Shares in Editas Medicine, Inc. (NASDAQ:EDIT)

Keystone Financial Group acquired a new stake in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 14,000 shares of the company’s stock, valued at approximately $115,000. A number of other institutional investors have also recently […]

Editas Medicine to Present Clinical Data from the RUBY and - Vimarsana News

Editas Medicine to Present Clinical Data from the RUBY and

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to...

Editas Medicine (EDIT) to Release Quarterly Earnings on Friday - Vimarsana News

Editas Medicine (EDIT) to Release Quarterly Earnings on Friday

Editas Medicine (NASDAQ:EDIT – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, November 3rd. Analysts expect the company to announce earnings of ($0.64) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link. […]

Editas Medicine (EDIT) – Investment Analysts' Recent Ratings Changes - Vimarsana News

Editas Medicine (EDIT) – Investment Analysts' Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Editas Medicine (NASDAQ: EDIT): 10/24/2023 – Editas Medicine was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $11.00 price target on the stock. 10/18/2023 – Editas Medicine was upgraded by analysts at […]